Okavax
Description
Description
Okavax vaccine contans attenuated Oka strain of Varicella zoster virus. It is indicated for prevention of Chickenpox in persons from 12 months of age.
Immunization Guideline
Immunization Guideline
A single dose of 0.5 mL is injected subcutaneously to persons not less than 12 months of age and with no history of chickenpox.
Additional information
Additional information
country-of-manufacture
Thailand
manufacturer
Sanofi Pasteur
package-size
1 Dose
pharmaceutical-form
Lyophilized
preservative
None
route-of-administration
Subcutaneous
vaccine-type
chickenpox
Contraindications
Those suffering from fever, acutely ill, having experienced a previous
anaphylactic reaction to the vaccine or any of its components. Pregnancy.